10/23/2013 8:27:14 AM
In a bid to retrieve tens of millions of dollars over the next several years, New York University has filed a lawsuit against Pfizer, claiming the drugmaker failed to pay royalties on its Xalkori medication, which was approved two years ago by the FDA to treat non-small cell lung cancer along with a diagnostic kit. The dispute is the latest example of a spat over the proceeds from research that is generated by academia but is commercialized by a drugmaker under a development deal. In this instance, NYU claims that Pfizer did not honor an agreement that was inherited as part of its 2003 acquisition of Pharmacia.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by